Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future.

Pierobon M, Petricoin EF 3rd, Wulfkuhle JD.

Expert Rev Proteomics. 2018 Oct 10:1-3. doi: 10.1080/14789450.2018.1531709. [Epub ahead of print] No abstract available.

PMID:
30301389
2.

Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma.

Cruickshanks N, Zhang Y, Hine S, Gibert M, Yuan F, Oxford M, Grello CM, Pahuski M, Dube C, Guessous F, Wang B, Deveau C, Saoud K, Gallagher RI, Wulfkuhle JD, Schiff D, Phan SC, Petricoin EF, Abounader R.

Clin Cancer Res. 2018 Sep 10. pii: clincanres.0926.2018. doi: 10.1158/1078-0432.CCR-18-0926. [Epub ahead of print]

PMID:
30201763
3.

Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells.

Tricoli L, Naeem A, Parasido E, Mikhaiel JP, Choudhry MU, Berry DL, Abdelgawad IA, Lee RJ, Feldman AS, Ihemelandu C, Avantaggiati M, Kumar D, Byers S, Gallagher R, Wulfkuhle J, Petricoin E, Rodriguez O, Albanese C.

Oncotarget. 2017 Dec 18;9(2):2193-2207. doi: 10.18632/oncotarget.23363. eCollection 2018 Jan 5.

4.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011014. doi: 10.1117/1.JMI.5.1.011014. Epub 2017 Dec 23.

PMID:
29296631
5.

Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.

Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkuhle JD, Gallagher RI, Petricoin EF Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA.

Cell Chem Biol. 2017 Oct 19;24(10):1314. doi: 10.1016/j.chembiol.2017.09.012. No abstract available.

PMID:
29053951
6.

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ.

Blood Adv. 2017 Jun 13;1(14):933-946. Erratum in: Blood Adv. 2017 Aug 17;1(19):1537.

7.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.

NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

8.

Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.

Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkuhle JD, Gallagher RI, Petricoin EF Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA.

Cell Chem Biol. 2017 Oct 19;24(10):1259-1275.e6. doi: 10.1016/j.chembiol.2017.08.009. Epub 2017 Sep 14.

9.

Targetable T-type Calcium Channels Drive Glioblastoma.

Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, Gallagher I, Koeppel AF, Hatef S, Papanicolas C, Lee J, Bar EE, Schiff D, Turner SD, Petricoin EF, Gray LS, Abounader R.

Cancer Res. 2017 Jul 1;77(13):3479-3490. doi: 10.1158/0008-5472.CAN-16-2347. Epub 2017 May 16.

10.

Innovations in Clinical Trial Design in the Era of Molecular Profiling.

Wulfkuhle JD, Spira A, Edmiston KH, Petricoin EF 3rd.

Methods Mol Biol. 2017;1606:19-36. doi: 10.1007/978-1-4939-6990-6_2. Review.

PMID:
28501991
11.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

12.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

13.

Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer.

Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C.

World J Clin Oncol. 2015 Dec 10;6(6):299-311. doi: 10.5306/wjco.v6.i6.299.

14.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

PMID:
26387536
15.

A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.

Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ.

Breast Cancer Res Treat. 2014 Oct;147(3):579-88. doi: 10.1007/s10549-014-3117-1. Epub 2014 Sep 11.

PMID:
25209003
16.

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

Pierobon M, Wulfkuhle J, Liotta L, Petricoin E.

Oncogene. 2015 Feb 12;34(7):805-14. doi: 10.1038/onc.2014.16. Epub 2014 Mar 10. Review.

PMID:
24608425
17.

Presence of anaplastic lymphoma kinase in inflammatory breast cancer.

Robertson FM, Petricoin Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsky SH, Sun G, Cristofanilli M.

Springerplus. 2013 Oct 1;2:497. doi: 10.1186/2193-1801-2-497. eCollection 2013.

18.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

19.

Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures.

Federici G, Gao X, Slawek J, Arodz T, Shitaye A, Wulfkuhle JD, De Maria R, Liotta LA, Petricoin EF 3rd.

Mol Cancer Res. 2013 Jun;11(6):676-85. doi: 10.1158/1541-7786.MCR-12-0690. Epub 2013 May 1.

20.

A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd.

J Thorac Oncol. 2012 Dec;7(12):1755-1766. doi: 10.1097/JTO.0b013e3182725fc7.

21.

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L; I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF 3rd.

Clin Cancer Res. 2012 Dec 1;18(23):6426-35. doi: 10.1158/1078-0432.CCR-12-0452. Epub 2012 Oct 8.

22.

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T.

Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14.

23.

Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.

van Agthoven T, Godinho MF, Wulfkuhle JD, Petricoin EF 3rd, Dorssers LC.

Int J Cancer. 2012 Nov 1;131(9):1998-2007. doi: 10.1002/ijc.27489. Epub 2012 Mar 20.

24.

Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins.

Raiszadeh MM, Ross MM, Russo PS, Schaepper MA, Zhou W, Deng J, Ng D, Dickson A, Dickson C, Strom M, Osorio C, Soeprono T, Wulfkuhle JD, Petricoin EF, Liotta LA, Kirsch WM.

J Proteome Res. 2012 Apr 6;11(4):2127-39. doi: 10.1021/pr2007957. Epub 2012 Feb 27.

25.

Asymmetric cancer cell division regulated by AKT.

Dey-Guha I, Wolfer A, Yeh AC, G Albeck J, Darp R, Leon E, Wulfkuhle J, Petricoin EF 3rd, Wittner BS, Ramaswamy S.

Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12845-50. doi: 10.1073/pnas.1109632108. Epub 2011 Jul 14.

26.

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.

Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF 3rd, Conaway M, Weber MJ.

Mol Cancer Ther. 2011 Sep;10(9):1581-90. doi: 10.1158/1535-7163.MCT-10-1033. Epub 2011 Jun 28.

27.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

28.

Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.

Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF 3rd, Wulfkuhle J, Liotta LA, Lem S, Baker JC Jr, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL.

Breast Cancer Res Treat. 2012 Apr;132(2):487-98. doi: 10.1007/s10549-011-1609-9. Epub 2011 Jun 7. Erratum in: Breast Cancer Res Treat. 2012 Oct;135(3):925.

29.

Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.

Improta G, Zupa A, Fillmore H, Deng J, Aieta M, Musto P, Liotta LA, Broaddus W, Petricoin EF 3rd, Wulfkuhle JD.

J Proteome Res. 2011 Jul 1;10(7):3089-97. doi: 10.1021/pr200065t. Epub 2011 May 27.

30.

High resolution mapping of the cardiac transmural proteome using reverse phase protein microarrays.

Anderson T, Wulfkuhle J, Petricoin E 3rd, Winslow RL.

Mol Cell Proteomics. 2011 Jul;10(7):M111.008037. doi: 10.1074/mcp.M111.008037. Epub 2011 Apr 13.

31.

Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.

Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfkuhle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):476-82. doi: 10.1158/1055-9965.EPI-10-0847. Epub 2011 Jan 17.

32.

Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.

Havaleshko DM, Smith SC, Cho H, Cheon S, Owens CR, Lee JK, Liotta LA, Espina V, Wulfkuhle JD, Petricoin EF, Theodorescu D.

Neoplasia. 2009 Nov;11(11):1185-93.

33.

Improved reproducibility of reverse-phase protein microarrays using array microenvironment normalization.

Anderson T, Wulfkuhle J, Liotta L, Winslow RL, Petricoin E 3rd.

Proteomics. 2009 Dec;9(24):5562-6. doi: 10.1002/pmic.200900505.

34.

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM.

J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45.

35.

Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer.

Gulmann C, Sheehan KM, Conroy RM, Wulfkuhle JD, Espina V, Mullarkey MJ, Kay EW, Liotta LA, Petricoin EF 3rd.

J Pathol. 2009 Aug;218(4):514-9. doi: 10.1002/path.2561.

PMID:
19396842
36.

Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment.

Espina V, Wulfkuhle J, Liotta LA.

Clin Lab Med. 2009 Mar;29(1):1-13. doi: 10.1016/j.cll.2009.03.001. Review.

PMID:
19389547
37.

Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures.

Grubb RL, Deng J, Pinto PA, Mohler JL, Chinnaiyan A, Rubin M, Linehan WM, Liotta LA, Petricoin EF, Wulfkuhle JD.

J Proteome Res. 2009 Jun;8(6):3044-54. doi: 10.1021/pr8009337.

38.

Molecular network analysis using reverse phase protein microarrays for patient tailored therapy.

Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd.

Adv Exp Med Biol. 2008;610:177-86. doi: 10.1007/978-0-387-73898-7_13. Review. No abstract available.

PMID:
18593023
39.

Reverse phase protein microarrays for theranostics and patient-tailored therapy.

Espina V, Wulfkuhle J, Calvert VS, Liotta LA, Petricoin EF 3rd.

Methods Mol Biol. 2008;441:113-28. doi: 10.1007/978-1-60327-047-2_8.

PMID:
18370315
40.

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA, Petricoin EF 3rd.

J Proteome Res. 2008 Apr;7(4):1508-17. doi: 10.1021/pr7008127. Epub 2008 Feb 8.

PMID:
18257519
41.

Reverse phase protein microarrays for monitoring biological responses.

Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3rd, Liotta LA.

Methods Mol Biol. 2007;383:321-36. doi: 10.1007/978-1-59745-335-6_21.

PMID:
18217695
42.

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.

Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E 3rd, Zhang Y.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63. Epub 2007 Oct 2. Erratum in: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19655.

43.

Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy.

Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):157-64. Review.

44.

The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.

Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF 3rd, Liotta LA, Abati A.

Cancer. 2007 Jun 25;111(3):173-84.

45.

Laser-capture microdissection.

Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, Geho DH, Petricoin EF 3rd, Liotta LA.

Nat Protoc. 2006;1(2):586-603.

PMID:
17406286
46.

Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.

Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd.

Nat Clin Pract Oncol. 2006 May;3(5):256-68. Review.

PMID:
16683004
47.

Reverse-phase protein microarrays for tissue-based analysis.

Speer R, Wulfkuhle JD, Liotta LA, Petricoin EF 3rd.

Curr Opin Mol Ther. 2005 Jun;7(3):240-5. Review.

PMID:
15977421
48.

Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays.

Geho D, Lahar N, Gurnani P, Huebschman M, Herrmann P, Espina V, Shi A, Wulfkuhle J, Garner H, Petricoin E 3rd, Liotta LA, Rosenblatt KP.

Bioconjug Chem. 2005 May-Jun;16(3):559-66.

PMID:
15898722
49.

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD.

Mol Cell Proteomics. 2005 Apr;4(4):346-55. Epub 2005 Jan 25. Review.

50.

Protein pathway analysis in Clinical Proteomics using protein microarrays.

Geho DH, Espina V, Wulfkuhle J, Petricoin EF, Liotta LA.

Drug Discov Today Technol. 2005 Winter;2(4):353-9. doi: 10.1016/j.ddtec.2005.11.008.

PMID:
24982012

Supplemental Content

Loading ...
Support Center